Targeting SLAMF7 to disrupt myeloma-osteoclast interaction: elotuzumab’s ADCC activity with Th1-like γδT cells towards osteoclasts and myeloma cells.
Targeting SLAMF7 to disrupt myeloma-osteoclast interaction: elotuzumab’s ADCC activity with Th1-like γδT cells towards osteoclasts and myeloma cells.
复制标题
靶向 SLAMF7 破坏骨髓瘤-破骨细胞相互作用：elotuzumab 与 Th1 样 γδT 细胞对破骨细胞和骨髓瘤细胞的 ADCC 活性。
DOI：
--
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Eiji Ta
中科院分区：
文献类型：
--
作者：
Hirofumi Tenshin;Takeshi Harada;Yusuke Inoue;Jumpei Teramachi;Masahiro Hiasa;Kotaro Tanimoto;So Shimizu;Yoshiki Higa;Emiko Nakaue;Masahiro Oura;Kimiko Sogabe;Tomoyo Hara;Ryohei Sumitani;Tomoko Maruhashi;Itsuro Endo;Toshio Matsumoto;Eiji Ta
